The medical sector thrives in research and development. It is this realization that Oncotarget, a weekly peer-reviewed medical journal was established in 2010. Basically, the publication started out as an online journal addressing issued related to oncology with its chief editorial team comprising of Dr. Mikhail Blagosklonny and Dr. Andrei Gudkov from the Institute of Cancer, Roswell Park. Over time, however, the publication has become a favorite of many thus forcing the editors to introduce other branches such as aging, pathology, cell death, microbiology, immunology, neuroscience, and autophagy. Despite this many branches the publication still maintains its key focus on oncology. Oncotarget is also available on Dove Press.
With the help of technology, oncotarget can quickly achieve its mission of making scientific research works easily and readily available to the whole world.
Unlike any other publication, oncotarget gives researchers a chance to share their works widely even though unfinished. Thanks to this platform, other scientists and researchers can weigh in their unbiased suggestions and comments regarding the thereby helping build on the content and making it complete.
On the part of scholars, oncotarget makes it easy to find research materials to use. Most scholars will agree with me finding research materials is not an easy thing to do these days. With the many patents, and copyrights available you will be required to either pay or look elsewhere for your research material. Now thanks to Oncotarget you have the permission to reprint, copy, reuse, distribute and modify a certain publication at the author’s permission free of charge.
To sum up the benefits of oncology is that the publication is available to in different languages. The publication editors ensure that every single user gets to access the valuable medical findings at whatever location they are at.
Oncotarget is a publication on a course to help make a positive impact in the world by making scientific research findings accessible to everybody, freely and easily. With its able authors and editors, this is not stopping anytime soon. Follow Oncotarget journal on Twitter.